Idorsia Ltd
SIX:IDIA

Watchlist Manager
Idorsia Ltd Logo
Idorsia Ltd
SIX:IDIA
Watchlist
Price: 0.917 CHF 1.44% Market Closed
Market Cap: 165.3m CHF

Idorsia Ltd
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Idorsia Ltd
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
Idorsia Ltd
SIX:IDIA
Total Liabilities & Equity
CHf500m
CAGR 3-Years
-30%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
AC Immune SA
NASDAQ:ACIU
Total Liabilities & Equity
CHf244.2m
CAGR 3-Years
6%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Total Liabilities & Equity
$2.3B
CAGR 3-Years
-7%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Molecular Partners AG
SIX:MOLN
Total Liabilities & Equity
CHf170.6m
CAGR 3-Years
-6%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Total Liabilities & Equity
CHf188.7m
CAGR 3-Years
-6%
CAGR 5-Years
-4%
CAGR 10-Years
-4%
Kuros Biosciences AG
SIX:KURN
Total Liabilities & Equity
CHf77.3m
CAGR 3-Years
-6%
CAGR 5-Years
-1%
CAGR 10-Years
N/A

Idorsia Ltd
Glance View

Market Cap
172.7m CHF
Industry
Biotechnology

Idorsia Ltd. operates as a biopharmaceutical firm which focuses on discovery, development and commercialization of innovative medicines for unmet medical needs. The company is headquartered in Allschwil, Basel-Landschaft. The company went IPO on 2017-06-16. The firm will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The firm's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.

IDIA Intrinsic Value
Not Available

See Also

What is Idorsia Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
500m CHF

Based on the financial report for Dec 31, 2023, Idorsia Ltd's Total Liabilities & Equity amounts to 500m CHF.

What is Idorsia Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
-19%

Over the last year, the Total Liabilities & Equity growth was -45%. The average annual Total Liabilities & Equity growth rates for Idorsia Ltd have been -30% over the past three years , -19% over the past five years .

Back to Top